(Q44563411)

4 December 2017

title

Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity (English)

1 reference

4 December 2017

3

1 reference

4 December 2017

S Goto

1

1 reference

4 December 2017

N Tamura

2

1 reference

4 December 2017

M Handa

4

1 reference

4 December 2017

Y Ikeda

5

1 reference

4 December 2017

S Handa

6

1 reference

4 December 2017

Z M Ruggeri

7

1 reference

4 December 2017

publication date

1 September 2003

1 reference

Journal of Thrombosis and Haemostasis

4 December 2017

published in

1 reference

4 December 2017

volume

1

1 reference

4 December 2017

issue

9

1 reference

4 December 2017

page(s)

2022-2030

1 reference

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00349.X

Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00349.X

Platelet GPIIb-IIIa blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00349.X

7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00349.X

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00349.X

Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00349.X

Activation of alphaVbeta3 on vascular cells controls recognition of prothrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00349.X

Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00349.X

Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00349.X

Functional significance of adenosine 5'-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00349.X

Antiplatelet agents in tissue factor-induced blood coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00349.X

Sequential cytoplasmic calcium signals in a 2-stage platelet activation process induced by the glycoprotein Ibalpha mechanoreceptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00349.X

Divalent cations regulate the organization of integrins alpha v beta 3 and alpha v beta 5 on the cell surface.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00349.X

Conformational regulation of integrin structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00349.X

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00349.X

Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb--IIIa inhibitors than by peptide and peptidomimetic inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00349.X

10.1046/J.1538-7836.2003.00349.X

21 January 2018

Identifiers

DOI

1 reference

4 December 2017

1 reference